Trial reportFrontiers in digital health2025
A randomized controlled trial on the application of a chronic disease management platform based on digital health technology combined with an innovative model of intelligent management for hypertension in patients with hypertension.
Trial report in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of digital health technologies in hypertension self-management: a narrative review.Frontiers in public health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Digital health technology (DHT)-based chronic disease management platforms combined with smart hypertension models may improve patient self-management. Objective: To compare the effect of Nantong University Affiliated Hospital's DHT platform combined with an intelligent hypertension management model (providing education, follow-up, evaluation) vs. traditional offline management on patients' systolic blood pressure (SBP). Design setting and participants: This was a two-arm, parallel-group randomized controlled trial conducted from July 2023 to March 2025. Participants were adults (≥18 years) with hypertension and uncontrolled blood pressure. Interventions: Participants were randomly assigned using computer-generated sequences to an integrated digital health platform with intelligent hypertension management (intervention, Main outcomes: Primary outcome: SBP at 12 months. Secondary outcomes: Diastolic blood pressure (DBP), BMI, biochemical/metabolic parameters (e.g., cholesterol, glucose, creatinine), and healthcare costs. Results: 547 participants completed the study (Intervention:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.